Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden†

Franck Morschhauser MD; Nicolas Mounier MD; Catherine Sebban MD; Pauline Brice MD; Phillippe Solal-Celigny MD; Herve Tilly MD; Pierre Feugier MD; Christophe Fermeacute; MD; Marie Christine Copin MD; Thierry Lamy MD

首页> 外文期刊>Cancer >Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden†

【24h】

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden†

机译：利妥昔单抗，氟达拉滨和米托蒽醌联合治疗初治，复发/难治性滤泡性非霍奇金淋巴瘤，高肿瘤负担的疗效和安全性†

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

This phase 2 trial was undertaken to evaluate the efficacy and safety of rituximab combined with intravenous fludarabine and mitoxantrone (R-FM) for patients with recurrent/refractory follicular lymphoma who had high tumor burden according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria.

机译：根据Groupe d'Etude des Lymphomes Folliculaires（GELF）进行的这项2期试验，评估了利妥昔单抗联合静脉注射氟达拉滨和米托蒽醌（R-FM）对患有高肿瘤负荷的复发/难治性滤泡性淋巴瘤患者的疗效和安全性标准。

著录项

来源
《Cancer 》 |2010年第18期| p.4299-4308| 共10页
作者
Franck Morschhauser MD; Nicolas Mounier MD; Catherine Sebban MD; Pauline Brice MD; Phillippe Solal-Celigny MD; Herve Tilly MD; Pierre Feugier MD; Christophe Fermeacute; MD; Marie Christine Copin MD; Thierry Lamy MD;
展开▼
作者单位

Hematology Department, Lille University Hospital Center, Lille, France;

Hematology Department, Nice University Hospital Center, Nice, France;

Hematology Department, Lyon Berard University Hospital Center, Lyon, France;

Hematology Department, University Hospital Center/St. Louis Hospital/Pubic Assistance Hospital of Paris, Paris, France;

Hematology Department, Victor Hugo Clinic, Le Mans, France;

Hematology Department, Henri Becquerel Center, Rouen, France;

Hematology Department, Brabois University Hospital enter, Nancy, France;

Hematology Department, Gustave Roussy Institute, Villejuif, France;

Hematology Department, Paoli Calmette Institute, Marseille, France;

Hematology Department, Pontchaillou University Hospital Center, Rennes, France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
follicular lymphoma; high tumor burden; fludarabine-based combination; immunochemotherapy;

机译：滤泡性淋巴瘤;高肿瘤负荷;以氟达拉滨为基础的联合疗法;免疫化学疗法;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucemies et Autres Maladies du Sang (GOELAMS). [J] . Morschhauser F, Mounier N, Sebban C, Cancer: A Journal of the American Cancer Society . 2010 ,第18期

机译：利妥昔单抗，氟达拉滨和米托蒽醌联合治疗初治的利妥昔单抗，复发/难治的非霍奇金滤泡性非霍奇金淋巴瘤的疗效和安全性：Groupe d'Etude des Lymphomes de l'Adulte（GELA）的多中心2期试验）和白血病和其他血液疾病的西东部组（GOELAMS）。
2. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. [J] . Karmali R, Kassar M, Venugopal P, Clinical lymphoma, myeloma & leukemia . 2011 ,第6期

机译：氟达拉滨，米托蒽醌和利妥昔单抗，钇90 ibritumomab替uxtan联合维持利妥昔单抗作为滤泡或边缘区淋巴瘤患者的一线治疗的安全性和有效性。
3. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi | Haematologica [J] . Stefano Sacchi, Raffaella Marcheselli, Alessia Bari, Haematologica . 2016 ,第5期

机译：来那度胺联合利妥昔单抗治疗复发性惰性非滤泡性淋巴瘤的安全性和有效性：Fondazione Italiana Linfomi进行的II期研究的最终结果|血液学
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi [O] . Stefano Sacchi, Raffaella Marcheselli, Alessia Bari, 2016

机译：来那度胺联合利妥昔单抗治疗复发性惰性非滤泡性淋巴瘤的安全性和有效性：Fondazione Italiana Linfomi进行的II期研究的最终结果
6. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS). [O] . Morschhauser, Franck, Mounier, Nicolas, Sebban, Catherine, 2010

机译：利妥昔单抗，氟达拉滨和米托蒽醌联合治疗初治的利妥昔单抗，复发/难治性滤泡性非霍奇金淋巴瘤的高肿瘤负担：成人淋巴瘤研究小组（GELA）的多中心2期试验）和白血病和其他血液疾病的西东部组织（GOELAMS）。

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden†

摘要

著录项

相似文献

相关主题

期刊订阅